Brief by Shorts91NewsDesk / 10:49am on 12 Apr 2025,Saturday Health & Wellness
A groundbreaking breast cancer drug, Capivasertib (Truqap), developed by AstraZeneca, has been approved for use in the NHS in England and Wales. This oral medication is targeted at hormone receptor-positive, HER2-negative breast cancer patients with specific genetic mutations. Capivasertib, when combined with hormone therapy, has shown promising results, increasing the time before disease progression. Clinical trials demonstrated a significant extension of progression-free survival, from 3.1 to 7.3 months. Experts are calling this a major step forward in personalized cancer treatment and recommend genetic testing for patients to access this life-changing treatment. (PC: The Guardian)
